CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

28 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

16 Jun 2021 08:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

06 May 2021 16:05:02 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

12 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

07 Apr 2021 18:31:23 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

30 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

24 Mar 2021 07:10:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

22 Mar 2021 07:10:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

12 Mar 2021 07:10:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

04 Feb 2021 07:10:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

03 Feb 2021 07:10:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference 

06 Jan 2021 07:05:00 By Nasdaq GlobeNewswire